Institutional Investors Increase AstraZeneca Holdings in Q3 2025

Multiple institutional investors significantly increased their holdings in AstraZeneca Plc during the third quarter of 2025, according to recent SEC filings. Clark Capital Management Group Inc. grew its position by 94.2% during the quarter, acquiring an additional 627,971 shares to bring its total holdings to 1,294,484 shares valued at $99,313,000.

Capitolis Liquid Global Markets LLC acquired a new position in AstraZeneca in the third quarter, purchasing 13,900 shares valued at approximately $1,066,000. Crestwood Advisors Group LLC boosted its holdings by 10.5% during the third quarter, buying an additional 50,068 shares to bring its total to 525,251 shares worth $40,297,000.

Several other institutional investors made substantial changes to their positions. Bank of Montreal Can lifted its stake by 344.6% in the third quarter, now holding 3,478,114 shares valued at $266,841,000 after buying an additional 2,695,793 shares. Fayez Sarofim & Co grew its position by 173.4% during the second quarter, acquiring an additional 2,376,032 shares to reach 3,745,902 shares worth $261,764,000.

Raymond James Financial Inc. grew its position by 64.8% during the second quarter, acquiring an additional 1,487,662 shares to reach 3,783,251 shares worth $264,373,000. Bank of America Corp DE increased its holdings by 4.7% in the third quarter, adding 1,461,786 shares to bring its total to 32,633,139 shares valued at $2,503,614,000. Ontario Teachers Pension Plan Board purchased a new stake in the second quarter valued at $96,936,000.

Additional institutional activity included Cibc World Market Inc., which raised its stake by 21.5% during the third quarter, now owning 64,421 shares valued at $4,942,000 after buying an additional 11,398 shares. TD Asset Management Inc grew its position by 20.0% in the third quarter, now holding 1,089,612 shares worth $83,595,000 after acquiring an additional 181,273 shares. Y Intercept Hong Kong Ltd increased its holdings by 111.6% in the third quarter, now holding 66,643 shares valued at $5,113,000 after acquiring an additional 35,148 shares.

AMG National Trust Bank increased its holdings by 20.4% in the third quarter, now holding 42,983 shares valued at $3,298,000 after acquiring an additional 7,289 shares. Oxbow Advisors LLC raised its position by 96.2% during the third quarter, now holding 77,594 shares valued at $5,953,000 after acquiring an additional 38,043 shares. Acadian Asset Management LLC raised its position by 2,389.9% in the second quarter, now holding 2,043,850 shares valued at $142,798,000 after purchasing an additional 1,961,764 shares. Jennison Associates LLC lifted its stake by 15.2% during the second quarter, now holding 12,167,365 shares worth $850,255,000 after buying an additional 1,605,133 shares.

Institutional investors and hedge funds own 20.35% of the company's stock.

Shares of AZN opened at $190.20, with the company having a market cap of $294.98 billion. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94. AstraZeneca has a 12 month low of $122.48 and a 12 month high of $212.71.

The company recently declared a dividend of $1.595 per share, which will be paid on Monday, March 23rd to stockholders of record on Friday, February 20th. The ex-dividend date is Friday, February 20th. AstraZeneca's dividend payout ratio is currently 66.26%.

Several equities research analysts recently issued reports on the company. Guggenheim reiterated a "buy" rating on shares of AstraZeneca in a research note on Wednesday, December 3rd. Wall Street Zen cut shares of AstraZeneca from a "buy" rating to a "hold" rating. HSBC reiterated a "buy" rating and issued a $108.00 price target on shares of AstraZeneca in a research report on Wednesday, December 10th. Citigroup initiated coverage on shares of AstraZeneca in a research report on Tuesday, January 27th, setting a "buy" rating for the company. Barclays reaffirmed an "overweight" rating on shares of AstraZeneca in a research report on Tuesday, January 6th. TD Cowen reiterated a "buy" rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Morgan Stanley reiterated an "overweight" rating and set a $103.00 target price on shares of AstraZeneca in a research note on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft reissued a "sell" rating on shares of AstraZeneca. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. AstraZeneca currently has a consensus rating of "Moderate Buy" and an average target price of $95.75.

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden's Astra AB and the UK's Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. The company's commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic diseases, and respiratory and immunology.